<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">33893375</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>11</Month>
        <Day>17</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>11</Month>
        <Day>17</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2045-2322</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>11</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Apr</Month>
              <Day>23</Day>
            </PubDate>
          </JournalIssue>
          <Title>Scientific reports</Title>
          <ISOAbbreviation>Sci Rep</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Aggressive and recurrent ovarian cancers upregulate ephrinA5, a non-canonical effector of EphA2 signaling duality.</ArticleTitle>
        <Pagination>
          <StartPage>8856</StartPage>
          <MedlinePgn>8856</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">8856</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-021-88382-6</ELocationID>
        <Abstract>
          <AbstractText>Erythropoietin producing hepatocellular (Eph) receptors and their membrane-bound ligands ephrins are variably expressed in epithelial cancers, with context-dependent implications to both tumor-promoting and -suppressive processes in ways that remain incompletely understood. Using ovarian cancer tissue microarrays and longitudinally collected patient cells, we show here that ephrinA5/EFNA5 is specifically overexpressed in the most aggressive high-grade serous carcinoma (HGSC) subtype, and increased in the HGSC cells upon disease progression. Among all the eight ephrin genes, high EFNA5 expression was most strongly associated with poor overall survival in HGSC patients from multiple independent datasets. In contrast, high EFNA3 predicted improved overall and progression-free survival in The Cancer Genome Atlas HGSC dataset, as expected for a canonical inducer of tumor-suppressive Eph receptor tyrosine kinase signaling. While depletion of either EFNA5 or the more extensively studied, canonically acting EFNA1 in HGSC cells increased the oncogenic EphA2-S897 phosphorylation, EFNA5 depletion left unaltered, or even increased the ligand-dependent EphA2-Y588 phosphorylation. Moreover, treatment with recombinant ephrinA5 led to limited EphA2 tyrosine phosphorylation, internalization and degradation compared to ephrinA1. Altogether, our results suggest a unique function for ephrinA5 in Eph-ephrin signaling and highlight the clinical potential of ephrinA5 as a cell surface biomarker in the most aggressive HGSCs.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Jukonen</LastName>
            <ForeName>Joonas</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Translational Cancer Medicine Research Program, University of Helsinki, 00140, Helsinki, Finland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Moyano-Galceran</LastName>
            <ForeName>Lidia</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, 171 77, Stockholm, Sweden.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Höpfner</LastName>
            <ForeName>Katrin</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Individualized Drug Therapy Research Program, University of Helsinki, 00140, Helsinki, Finland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pietilä</LastName>
            <ForeName>Elina A</ForeName>
            <Initials>EA</Initials>
            <AffiliationInfo>
              <Affiliation>Individualized Drug Therapy Research Program, University of Helsinki, 00140, Helsinki, Finland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lehtinen</LastName>
            <ForeName>Laura</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Biomedicine, University of Turku, 20520, Turku, Finland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Huhtinen</LastName>
            <ForeName>Kaisa</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Biomedicine, University of Turku, 20520, Turku, Finland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gucciardo</LastName>
            <ForeName>Erika</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Individualized Drug Therapy Research Program, University of Helsinki, 00140, Helsinki, Finland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hynninen</LastName>
            <ForeName>Johanna</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Obstetrics and Gynecology, Turku University Hospital, University of Turku, 20521, Turku, Finland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hietanen</LastName>
            <ForeName>Sakari</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Obstetrics and Gynecology, Turku University Hospital, University of Turku, 20521, Turku, Finland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Grénman</LastName>
            <ForeName>Seija</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Obstetrics and Gynecology, Turku University Hospital, University of Turku, 20521, Turku, Finland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ojala</LastName>
            <ForeName>Päivi M</ForeName>
            <Initials>PM</Initials>
            <AffiliationInfo>
              <Affiliation>Translational Cancer Medicine Research Program, University of Helsinki, 00140, Helsinki, Finland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Carpén</LastName>
            <ForeName>Olli</ForeName>
            <Initials>O</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Biomedicine, University of Turku, 20520, Turku, Finland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lehti</LastName>
            <ForeName>Kaisa</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, 171 77, Stockholm, Sweden. kaisa.lehti@ntnu.no.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Individualized Drug Therapy Research Program, University of Helsinki, 00140, Helsinki, Finland. kaisa.lehti@ntnu.no.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Biomedical Laboratory Science, Norwegian University of Science and Technology, 7491, Trondheim, Norway. kaisa.lehti@ntnu.no.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>04</Month>
          <Day>23</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Sci Rep</MedlineTA>
        <NlmUniqueID>101563288</NlmUniqueID>
        <ISSNLinking>2045-2322</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D014408">Biomarkers, Tumor</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C000623258">EPHA2 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D036386">Ephrin-A5</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.10.1</RegistryNumber>
          <NameOfSubstance UI="D036104">Receptor, EphA2</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D014408" MajorTopicYN="N">Biomarkers, Tumor</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D036386" MajorTopicYN="N">Ephrin-A5</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009364" MajorTopicYN="Y">Neoplasm Recurrence, Local</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010051" MajorTopicYN="N">Ovarian Neoplasms</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D036104" MajorTopicYN="N">Receptor, EphA2</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016019" MajorTopicYN="N">Survival Analysis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015854" MajorTopicYN="Y">Up-Regulation</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>The authors declare no competing interests.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>12</Month>
          <Day>17</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>4</Month>
          <Day>8</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>4</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>2</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>4</Month>
          <Day>25</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33893375</ArticleId>
        <ArticleId IdType="pmc">PMC8065122</ArticleId>
        <ArticleId IdType="doi">10.1038/s41598-021-88382-6</ArticleId>
        <ArticleId IdType="pii">10.1038/s41598-021-88382-6</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Bray F, et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018;68:394–424.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30207593</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Howlader, N. et al. SEER Cancer Statistics Review, 1975–2014. https://seer.cancer.gov/csr/1975_2014/ (National Cancer Institute. Bethesda, MD, 2017).</Citation>
        </Reference>
        <Reference>
          <Citation>Torre LA, et al.  Ovarian cancer statistics, 2018. CA Cancer J. Clin. 2018;68:284–296. doi: 10.3322/caac.21456.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3322/caac.21456</ArticleId>
            <ArticleId IdType="pmc">PMC6621554</ArticleId>
            <ArticleId IdType="pubmed">29809280</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lisio MA, Fu L, Goyeneche A, Gao ZH, Telleria C. High-grade serous ovarian cancer: basic sciences, clinical and therapeutic standpoints. Int. J. Mol. Sci. 2019;20:952. doi: 10.3390/ijms20040952.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ijms20040952</ArticleId>
            <ArticleId IdType="pmc">PMC6412907</ArticleId>
            <ArticleId IdType="pubmed">30813239</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>FDA approves niraparib for first-line maintenance of advanced ovarian cancer. https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-niraparib-first-line-maintenance-advanced-ovarian-cancer (2020).</Citation>
        </Reference>
        <Reference>
          <Citation>FDA approves bevacizumab in combination with chemotherapy for ovarian cancer. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-bevacizumab-combination-chemotherapy-ovarian-cancer (2018).</Citation>
        </Reference>
        <Reference>
          <Citation>Mahmood RD, Morgan RD, Edmondson RJ, Clamp AR, Jayson GC. First-line management of advanced high-grade serous ovarian cancer. Curr. Oncol. Rep. 2020;22:64. doi: 10.1007/s11912-020-00933-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11912-020-00933-8</ArticleId>
            <ArticleId IdType="pmc">PMC7270049</ArticleId>
            <ArticleId IdType="pubmed">32494876</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>González-Martín A, et al.  Niraparib in patients with newly diagnosed advanced ovarian cancer. N. Engl. J. Med. 2019;381:2391–2402. doi: 10.1056/NEJMoa1910962.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1910962</ArticleId>
            <ArticleId IdType="pubmed">31562799</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tewari KS, et al.  Final overall survival of a randomized trial of bevacizumab for primary treatment of ovarian cancer. J. Clin. Oncol. 2019;37:2317–2328. doi: 10.1200/JCO.19.01009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.19.01009</ArticleId>
            <ArticleId IdType="pmc">PMC6879307</ArticleId>
            <ArticleId IdType="pubmed">31216226</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Matulonis UA, et al.  Ovarian cancer. Nat. Rev. Dis. Prim. 2016;2:1–22.</Citation>
        </Reference>
        <Reference>
          <Citation>Kania A, Klein R. Mechanisms of ephrin-Eph signalling in development, physiology and disease. Nat. Rev. Mol. Cell Biol. 2016;17:240–256. doi: 10.1038/nrm.2015.16.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrm.2015.16</ArticleId>
            <ArticleId IdType="pubmed">26790531</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pasquale EB. Eph receptors and ephrins in cancer: bidirectional signalling and beyond. Nat. Rev. Cancer. 2010;10:165–180. doi: 10.1038/nrc2806.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrc2806</ArticleId>
            <ArticleId IdType="pmc">PMC2921274</ArticleId>
            <ArticleId IdType="pubmed">20179713</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Himanen JP, Nikolov DB. Eph signaling: a structural view. Trends Neurosci. 2003;26:46–51. doi: 10.1016/S0166-2236(02)00005-X.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0166-2236(02)00005-X</ArticleId>
            <ArticleId IdType="pubmed">12495863</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Taylor H, Campbell J, Nobes CD. Ephs and ephrins. Curr. Biol. 2017;27:R90–R95. doi: 10.1016/j.cub.2017.01.003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cub.2017.01.003</ArticleId>
            <ArticleId IdType="pubmed">28171762</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kandouz M. The Eph/Ephrin family in cancer metastasis: communication at the service of invasion. Cancer Metastasis Rev. 2012;31:353–373. doi: 10.1007/s10555-012-9352-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10555-012-9352-1</ArticleId>
            <ArticleId IdType="pubmed">22549394</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Han L, et al.  The clinical significance of EphA2 and Ephrin A-1 in epithelial ovarian carcinomas. Gynecol. Oncol. 2005;99:278–286. doi: 10.1016/j.ygyno.2005.06.036.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ygyno.2005.06.036</ArticleId>
            <ArticleId IdType="pubmed">16061279</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alam SM, Fujimoto J, Jahan I, Sato E, Tamaya T. Coexpression of EphB4 and ephrinB2 in tumour advancement of ovarian cancers. Br. J. Cancer. 2008;98:845–851. doi: 10.1038/sj.bjc.6604216.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/sj.bjc.6604216</ArticleId>
            <ArticleId IdType="pmc">PMC2259170</ArticleId>
            <ArticleId IdType="pubmed">18231102</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Herath NI, et al.  Over-expression of Eph and ephrin genes in advanced ovarian cancer: Ephrin gene expression correlates with shortened survival. BMC Cancer. 2006;6:144. doi: 10.1186/1471-2407-6-144.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1471-2407-6-144</ArticleId>
            <ArticleId IdType="pmc">PMC1501040</ArticleId>
            <ArticleId IdType="pubmed">16737551</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu X, et al.  EphA8 is a prognostic marker for epithelial ovarian cancer. Oncotarget. 2016;7:20801–20809. doi: 10.18632/oncotarget.8018.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.8018</ArticleId>
            <ArticleId IdType="pmc">PMC4991493</ArticleId>
            <ArticleId IdType="pubmed">26989075</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang L, Bie L, Sun L, Yue Y. Neural activities are unfavorable for the prognosis of ovarian cancer through mRNA expression analysis. Biomark. Med. 2019;13:663–674. doi: 10.2217/bmm-2019-0056.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2217/bmm-2019-0056</ArticleId>
            <ArticleId IdType="pubmed">30982327</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bao M, Zhang L, Hu Y. Novel gene signatures for prognosis prediction in ovarian cancer. J. Cell. Mol. Med. 2020;24:9972–9984. doi: 10.1111/jcmm.15601.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/jcmm.15601</ArticleId>
            <ArticleId IdType="pmc">PMC7520318</ArticleId>
            <ArticleId IdType="pubmed">32666642</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reinartz S, et al.  A transcriptome-based global map of signaling pathways in the ovarian cancer microenvironment associated with clinical outcome. Genome Biol. 2016;17:108. doi: 10.1186/s13059-016-0956-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13059-016-0956-6</ArticleId>
            <ArticleId IdType="pmc">PMC4877997</ArticleId>
            <ArticleId IdType="pubmed">27215396</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang H, et al.  Loss of expression of EphB1 protein in serous carcinoma of ovary associated with metastasis and poor survival. Int. J. Clin. Exp. Pathol. 2014;7:313–321.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3885486</ArticleId>
            <ArticleId IdType="pubmed">24427352</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jin Y, et al.  Decreased Eph receptor-A1 expression is related to grade in ovarian serous carcinoma. Mol. Med. Rep. 2018;17:5409–5415.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29393455</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gu Y, et al.  Expression of EphB6 in ovarian serous carcinoma is associated with grade, TNM stage and survival. J. Clin. Pathol. 2016;69:448–453. doi: 10.1136/jclinpath-2015-203160.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jclinpath-2015-203160</ArticleId>
            <ArticleId IdType="pubmed">26468391</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cui Y, et al.  Knockdown of EPHA1 using crispr/cas9 suppresses aggressive properties of ovarian cancer cells. Anticancer Res. 2017;37:4415–4424.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28739735</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xiao T, et al.  Targeting EphA2 in cancer. J. Hematol. Oncol. 2020;13:114. doi: 10.1186/s13045-020-00944-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13045-020-00944-9</ArticleId>
            <ArticleId IdType="pmc">PMC7433191</ArticleId>
            <ArticleId IdType="pubmed">32811512</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Murai KK, Pasquale EB. ’Eph’ective signaling: forward, reverse and crosstalk. J. Cell Sci. 2003;116:2823–2832. doi: 10.1242/jcs.00625.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1242/jcs.00625</ArticleId>
            <ArticleId IdType="pubmed">12808016</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moyano-Galceran L, et al.  Adaptive RSK-EphA2-GPRC5A signaling switch triggers chemotherapy resistance in ovarian cancer. EMBO Mol. Med. 2020;12:e11177. doi: 10.15252/emmm.201911177.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.15252/emmm.201911177</ArticleId>
            <ArticleId IdType="pmc">PMC7136956</ArticleId>
            <ArticleId IdType="pubmed">32115889</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barquilla A, et al.  Protein kinase A can block EphA2 receptor-mediated cell repulsion by increasing EphA2 S897 phosphorylation. Mol. Biol. Cell. 2016;27:2757–2770. doi: 10.1091/mbc.e16-01-0048.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1091/mbc.e16-01-0048</ArticleId>
            <ArticleId IdType="pmc">PMC5007095</ArticleId>
            <ArticleId IdType="pubmed">27385333</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miao H, et al.  EphA2 mediates ligand-dependent inhibition and ligand-independent promotion of cell migration and invasion via a reciprocal regulatory loop with Akt. Cancer Cell. 2009;16:9–20. doi: 10.1016/j.ccr.2009.04.009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ccr.2009.04.009</ArticleId>
            <ArticleId IdType="pmc">PMC2860958</ArticleId>
            <ArticleId IdType="pubmed">19573808</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sugiyama N, et al.  Epha2 cleavage by MT1-MMP triggers single cancer cell invasion via homotypic cell repulsion. J. Cell Biol. 2013;201:467–484. doi: 10.1083/jcb.201205176.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1083/jcb.201205176</ArticleId>
            <ArticleId IdType="pmc">PMC3639392</ArticleId>
            <ArticleId IdType="pubmed">23629968</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Engelberth SA, Hempel N, Bergkvist M. Development of nanoscale approaches for ovarian cancer therapeutics and diagnostics. Crit. Rev. Oncog. 2014;19:281–316. doi: 10.1615/CritRevOncog.2014011455.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1615/CritRevOncog.2014011455</ArticleId>
            <ArticleId IdType="pmc">PMC4183979</ArticleId>
            <ArticleId IdType="pubmed">25271436</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Choi HJ, et al.  Anti-vascular therapies in ovarian cancer: moving beyond anti-VEGF approaches. Cancer Metastasis Rev. 2015;34:19–40. doi: 10.1007/s10555-014-9538-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10555-014-9538-9</ArticleId>
            <ArticleId IdType="pmc">PMC4369424</ArticleId>
            <ArticleId IdType="pubmed">25544368</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bell D, et al.  Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474:609–615. doi: 10.1038/nature10166.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature10166</ArticleId>
            <ArticleId IdType="pmc">PMC3163504</ArticleId>
            <ArticleId IdType="pubmed">21720365</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ganzfried BF, et al.  curatedOvarianData: clinically annotated data for the ovarian cancer transcriptome. Database (Oxford) 2013;2013:bat013. doi: 10.1093/database/bat013.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/database/bat013</ArticleId>
            <ArticleId IdType="pmc">PMC3625954</ArticleId>
            <ArticleId IdType="pubmed">23550061</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Takeuchi S, Katoh H, Negishi M. Eph/ephrin reverse signalling induces axonal retraction through RhoA/ROCK pathway. J. Biochem. 2015;158:245–252. doi: 10.1093/jb/mvv042.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/jb/mvv042</ArticleId>
            <ArticleId IdType="pubmed">25922200</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Koshikawa N, et al.  Proteolysis of EphA2 converts it from a tumor suppressor to an oncoprotein. Cancer Res. 2015;75:3327–3339. doi: 10.1158/0008-5472.CAN-14-2798.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-14-2798</ArticleId>
            <ArticleId IdType="pmc">PMC4682662</ArticleId>
            <ArticleId IdType="pubmed">26130649</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Domcke S, Sinha R, Levine DA, Sander C, Schultz N. Evaluating cell lines as tumour models by comparison of genomic profiles. Nat. Commun. 2013;4:2126. doi: 10.1038/ncomms3126.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncomms3126</ArticleId>
            <ArticleId IdType="pmc">PMC3715866</ArticleId>
            <ArticleId IdType="pubmed">23839242</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pabbisetty KB, et al.  Kinetic analysis of the binding of monomeric and dimeric ephrins to Eph receptors: correlation to function in a growth cone collapse assay. Protein Sci. 2007;16:355–361. doi: 10.1110/ps.062608807.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1110/ps.062608807</ArticleId>
            <ArticleId IdType="pmc">PMC2203307</ArticleId>
            <ArticleId IdType="pubmed">17322526</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Verheyen T, et al.  Spatial organization-dependent EphA2 transcriptional responses revealed by ligand nanocalipers. Nucleic Acids Res. 2020;48:5777–5787. doi: 10.1093/nar/gkaa274.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/nar/gkaa274</ArticleId>
            <ArticleId IdType="pmc">PMC7261182</ArticleId>
            <ArticleId IdType="pubmed">32352518</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Seiradake E, Harlos K, Sutton G, Aricescu AR, Jones EY. An extracellular steric seeding mechanism for Eph-ephrin signaling platform assembly. Nat. Struct. Mol. Biol. 2010;17:398–402. doi: 10.1038/nsmb.1782.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nsmb.1782</ArticleId>
            <ArticleId IdType="pmc">PMC3672960</ArticleId>
            <ArticleId IdType="pubmed">20228801</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Singh DR, Kanvinde P, King C, Pasquale EB, Hristova K. Erratum: author correction: the EphA2 receptor is activated through induction of distinct, ligand-dependent oligomeric structures. Commun. Biol. 2018;1:40. doi: 10.1038/s42003-018-0044-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s42003-018-0044-4</ArticleId>
            <ArticleId IdType="pmc">PMC6123739</ArticleId>
            <ArticleId IdType="pubmed">30273417</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Himanen J-P, et al.  Repelling class discrimination: ephrin-A5 binds to and activates EphB2 receptor signaling. Nat. Neurosci. 2004;7:501–509. doi: 10.1038/nn1237.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nn1237</ArticleId>
            <ArticleId IdType="pubmed">15107857</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Poitz DM, et al.  EphrinB2/EphA4-mediated activation of endothelial cells increases monocyte adhesion. Mol. Immunol. 2015;68:648–656. doi: 10.1016/j.molimm.2015.10.009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.molimm.2015.10.009</ArticleId>
            <ArticleId IdType="pubmed">26552760</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Icay K, et al.  SePIA: RNA and small RNA sequence processing, integration, and analysis. BioData Min. 2016;9:20. doi: 10.1186/s13040-016-0099-z.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13040-016-0099-z</ArticleId>
            <ArticleId IdType="pmc">PMC4875694</ArticleId>
            <ArticleId IdType="pubmed">27213017</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics. 2014;30:2114–2120. doi: 10.1093/bioinformatics/btu170.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/bioinformatics/btu170</ArticleId>
            <ArticleId IdType="pmc">PMC4103590</ArticleId>
            <ArticleId IdType="pubmed">24695404</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roberts A, Pachter L. Streaming fragment assignment for real-time analysis of sequencing experiments. Nat. Methods. 2013;10:71–73. doi: 10.1038/nmeth.2251.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nmeth.2251</ArticleId>
            <ArticleId IdType="pmc">PMC3880119</ArticleId>
            <ArticleId IdType="pubmed">23160280</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Myöhänen TT, Pyykkö E, Männistö PT, Carpen O. Distribution of prolyl oligopeptidase in human peripheral tissues and in ovarian and colorectal tumors. J. Histochem. Cytochem. 2012;60:706–715. doi: 10.1369/0022155412453051.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1369/0022155412453051</ArticleId>
            <ArticleId IdType="pmc">PMC3524555</ArticleId>
            <ArticleId IdType="pubmed">22740343</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Babicki S, et al.  Heatmapper: web-enabled heat mapping for all. Nucleic Acids Res. 2016;44:W147–W153. doi: 10.1093/nar/gkw419.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/nar/gkw419</ArticleId>
            <ArticleId IdType="pmc">PMC4987948</ArticleId>
            <ArticleId IdType="pubmed">27190236</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
